

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/309144253>

Back on Track: New Perspectives on Cancer Cell Reprogramming

Article · January 2016

DOI: 10.4172/2168-9431.1000151

CITATION

1

READS

33

3 authors, including:



Alessandra Gambacurta

University of Rome Tor Vergata

43 PUBLICATIONS 349 CITATIONS

[SEE PROFILE](#)

Some of the authors of this publication are also working on these related projects:



Molecular Imaging for Basic Science and Personalized and Intelligent Medicine [View project](#)



Role of endogenous retroviruses in cancer cell stemness [View project](#)

Back on Track: New Perspectives on Cancer Cell Reprogramming

Carpentieri Arianna^{*}, Diedenhofen Giacomo and Gambacurta Alessandra^{*}

Biochemistry Laboratory, Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome 00133, Italy

^{*}**Corresponding authors:** Arianna Carpentieri and Alessandra Gambacurta, Biochemistry Laboratory, Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, via Montpellier 1, Rome 00133, Italy, Tel/Fax: +39 06 72596488; E-mail: arianna6@live.it, gambacurta@med.uniroma2.it

Rec date: Sep 09, 2016; **Acc date:** Sep 23, 2016; **Pub date:** Sep 26, 2016

Copyright: © 2016 Arianna C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

The possibility to obtain induced pluripotent stem cells (iPSCs) starting from cancer cells has revealed itself to be a major step forward in the understanding of the mechanisms able to regulate stemness, differentiation and neoplastic transformation. Our work proposes a new differentiation method using rapamycin and an amorphous bone matrix to promote the commitment of neuroblastoma cells towards the osteogenic lineage, switching to a different germ layer, without an intermediate iPSCs step. We followed the process from a morphological point of view with immunofluorescence analysis, cytochemistry and electron microscopy and from a metabolic point of view with enzyme activity tests and protein expression analysis. We believe that the morphological and metabolic changes observed are the foundations for a new type of cancer cell reprogramming.

Keywords: Neuroblastoma; Cancer cell differentiation; Rapamycin; Scaffolds; Metabolic reprogramming

Commentary

One of the greatest challenges cancer researchers face is unraveling the complex network of cellular signals and events that leads to cancer onset and progression. By approaching the study of cancer from different angles and viewpoints, we can expect to deepen our understanding and paint a richer picture of this network. Progress has been made by reprogramming cancer cells into iPSCs to then differentiate them into various cell types, however we were intrigued by the possibility to reach this end result more directly. The paper “differentiation of human neuroblastoma cells toward the osteogenic lineage by mTOR inhibitor” [1] demonstrates the possibility to directly differentiate a human neuroblastoma cell line (SH-SY5Y) into osteoblast-like cells, without the intermediate step of forming iPSCs by inserting transcription factors [2]. Given this evidence, can we hope that another type of “reprogramming” is possible?

It is well known that a reprogramming of the healthy cell is observed during tumorigenesis, led by genetic mutations and/or physiological disturbances that deregulate basic processes in cellular homeostasis and, often also thanks to the tumor microenvironment, allow the acquisition of “stemness” features. This greater “stemness” leads to a particularly aggressive cancer phenotype with a greater tendency to form metastases. What is shared by the entire cancer population is a phenomenon known as “metabolic reprogramming”, during which the cells favour energy production through the glycolytic pathway even in normoxic conditions, at the expense of the oxidative phosphorylation pathway. This phenomenon together with lactate production is recognized as the Warburg effect [3,4].

We chose a human neuroblastoma cell line, SH-SY5Y, which is a highly aggressive and undifferentiated neuroendocrine cancer type derived from the neural crest. It provided us with a good and appropriate model to test the possibility of forcing a cancer cell to differentiate into a distinct germ layer sheet with respect to its origins. The aspects considered in this paper are both morphological and


metabolic changes that occur during the differentiation process of the cancer cell towards a new found normalcy, at the end of which most of the acquired malignancy characteristics are not being expressed anymore.

Our osteogenic differentiation protocol is based on rapamycin, already used for the differentiation of embryonic stem cells [5], combined with a second fundamental component: bone matrix granules acting as a scaffold to promote the differentiation process towards the osteogenic lineage. These matrix granules mimic the natural microenvironment in which osteoblasts act and physiologically reside. The key role of these granules is confirmed by SEM analysis, thanks to which we can observe osteoblast-like cells adhere to the scaffold. Multiple imaging techniques also confirmed the production of inorganic calcium phosphates and secretion of osteocalcin a typical osteogenesis marker.

Another important aspect highlighted in this article is the metabolic reorganization (glycolytic to oxidative) that occurs in differentiated cells under the guide of important transcription factors such as Myc and p53 [6]. In our cells we observe a change in protein expression characterized by a disappearance of Myc expression and a downregulation of p53. This metabolic switch is evidenced by a modulation in the expression of glycolysis enzymes, with a lowered expression of the glycolytic enzyme isoforms involved in the Warburg effect such as HK2, IDH2 and PKM2 [7]. Concomitantly, we observe an increase in oxidative phosphorylation, as deduced by the decreased ATP content in differentiated cells compared to SH-SY5Y cells, following the *in vitro* inhibition of the mitochondrial electron transport chain. Restoration of mitochondrial activity is accompanied by a marked increase in Sirt3 activity [8].

This paper presents an alternative approach to cancer cell reprogramming towards a differentiated state, by skipping the iPSCs production passage usually found in the literature [9]. We supposed that cancer cells already showed sufficient stem-cell-like behavior to be ready for direct differentiation towards other germ layer lineages. In this context we were able to avoid problems correlated with iPSCs generation such as variable induction efficiency and culture time,

depending on the methodology used [10,11]. Our data suggest that this simplified approach is viable, at least for the SH-SY5Y neuroblastoma cell line (Figure 1).



The guiding concept of this work is to consider the cancer cell population as a collection of cells that present a heterogenous mix of phenotypes, with varied degrees of differentiation, proliferation index and invasivity. Keeping this in mind, one could view the neoplastic

transformation as a form of faulty deprogramming of the adult cell. If this were true, the right perspective might not be one of cellular destruction but rather of “reeducation”, turning the evolutionary advantages acquired by the cancer cell to our favour by identifying the right stimuli to do so.

In conclusion, it appears clear that there are still multiple aspects of metabolic regulation and cellular differentiation that require further exploration. We believe that this novel protocol has the potential to change our approach to cancer reprogramming and provides a model to decipher the metabolic switch underlying it. It would be of interest to verify our hypothesis on other types of cancer cells as well, and we hope that this reprogramming strategy could open up a new scenario to aid us in better understanding the mechanisms behind the neoplastic transformation.

References

1. Carpentieri A, Cozzoli E, Scimeca M, Bonanno E, Sardanelli AM, et al. (2015) Differentiation of human neuroblastoma cells toward the osteogenic lineage by mTOR inhibitor. *Cell Death Dis* e1974.
2. Ramos-Mejia V, Fraga MF, Menendez P (2012) iPSCs from cancer cells: challenges and opportunities. *Trends Mol Med* 18: 5-8.
3. Warburg O, Posener K, Negelein E (1930) Ueber den stoffwechsel der tumoren. *Biochem Z* 152: 319-344.
4. Warburg O (1956) On the origin of cancer cells. *Science* 123: 309-314.
5. Lee KW, Yook JY, Son MY, Kim MJ, Koo DB, et al. (2010) Rapamycin promotes the osteoblastic differentiation of human embryonic stem cells by blocking the mTOR pathway and stimulating the BMP/Smad pathway. *Stem Cells Dev* 19: 557-568.
6. Yeung SJ, Pan J, Lee MH (2008) Roles of p53, MYC and HIF-1 in regulating glycolysis - the seventh hallmark of cancer. *Cell Mol Life Sci* 65: 3981-3999.
7. Ward PS, Thompson CB (2012) Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. *Cancer Cell* 21: 297-308.
8. Chen Y, Fu LL, Wen X, Wang XY, Liu J, et al. (2014) Sirtuin-3 (SIRT3), a therapeutic target with oncogenic and tumor-suppressive function in cancer. *Cell Death Dis* 5: e1047.
9. Zhang X, Cruz FD, Terry M, Remotti F, Matushansky I (2013) Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming. *Oncogene* 32: 2249-2260.
10. Ramos-Mejia V, Fraga MF, Menendez P (2012) iPSCs from cancer cells: challenges and opportunities. *Trends Mol Med* 18: 5-8.
11. Lim KL, Teoh HK, Choong PF, Teh HX, Cheong SK, et al. (2016) Reprogramming cancer cells: overview & current progress. *Expert Opin Biol Ther* 16: 941-951.